The page you are looking for can't be found. Go back or browse our recent articles below.

Go back home

Orexo announces positive outcome from in vivo study of OX390

IND Julian English -
Orexo AB has announced positive data from a pre-clinical in vivo study on the nasal absorption of atipamezole when delivered with...

MEKanistic Therapeutics announces FDA clearance of IND for MTX-531, enabling phase 1 trials in advanced solid tumours

IND Julian English -
MEKanistic Therapeutics, a biotechnology company developing first-in-class precision medicines designed to overcome cancer resistance mechanisms, has announced that the...

Matter Bio files first IND for Lm-LLO-TT, advancing first-in-human phase 1/2a study in patients with pancreatic cancer

IND Julian English -
Matter Bio has submitted its first Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for Lm-LLO-TT,...

Myosin Therapeutics initiates phase 1/2 trial of MT-125 targeting non-muscle myosin II in newly diagnosed glioblastoma

Phase 1-2 trials Julian English -
Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, has announced that the first patient has...

New clinical study shows pasteurised Akkermansia muciniphila MucT supports weight loss maintenance

Drug Discovery Julian English -
The Akkermansia company has announced the publication of a new randomised, placebo-controlled clinical trial in Nature Medicine demonstrating that supplementation with pasteurised Akkermansia...

Remepy reports strong clinical phase 2a results for Hybridopa, a first-in-class hybrid drug for Parkinson’s disease

Phase 1-2 trials Julian English -
Remepy, a pioneer in hybrid drugs, has announced that the phase 2a clinical trial of Hybridopa, a new hybrid...
spot_imgspot_img

BioMarin announces positive phase 3 pivotal study results for Voxzogo (vosoritide) in children with hypochondroplasia

Phase 3 trials Julian English -
BioMarin Pharmaceutical has announced that a phase 3 study evaluating treatment with Voxzogo® (vosoritide) in children with hypochondroplasia met its...

Atossa Therapeutics announces acceptance of manuscript highlighting utrophin-modulation potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Drug Discovery Julian English -
Atossa Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need,...

Eli Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal phase 3 obesity trial

Phase 3 trials Julian English -
Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has announced positive topline results from a...

Kelun-Biotech announces phase 3 trial of Sacituzumab Tirumotecan versus chemotherapy as first-line treatment for advanced TNBC met primary endpoint of PFS

Phase 3 trials Julian English -
Kelun-Biotech Biopharmaceutical has announced that the Independent Data Monitoring Committee (IDMC) concluded that the phase 3 clinical study of...

Eli Lilly announces three acquisitions to build infectious disease portfolio

Finance, mergers and appointments Julian English -
Eli Lilly and Company has entered agreements to acquire three companies, Curevo Inc, LimmaTech Biologic, and Vaccine Company, to expand its research and...

Positive topline results from a phase 3 trial for VGX-3100 in cervical dysplasia patients announced by ApolloBio, INOVIO’s partner in China

Phase 3 trials Julian English -
Inovio, a biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related...
Load more